Kosin Med J.  2012 Jun;27(1):1-9. 10.7180/kmj.2012.27.1.1.

Circulating Tumor Cells and Extracellular Nucleic Acids in Breast Cancer

• Ryu DW
• Lee CH

• KMID: 1993580
• DOI: http://doi.org/10.7180/kmj.2012.27.1.1

Abstract

Circulating tumor cells (CTCs) are defined as tumor cells circulating in the peripheral blood of patients, shed from either the primary tumor or from its metastases. The detection of circulating tumor cells (CTCs) in the peripheral blood of breast cancer patients may account for the different steps in the biologic progression of the disease. The detection of microscopic disease in patients with breast cancer is imperative to prognosis and can predict the efficacy of targeted treatments. In general, there are two main methods for their detection. These are based on cytometric and nucleic acid manipulation. Both methods generally require an enrichment step to increase sensitivity of the assay. This step is based on either detection of specific surface markers using immuno-selection and/or on morphological features, such as cell size or density. We review the methods of detecting CTCs, their prognostic implications, and opportunities to exploit the properties of CTCs to develop personalized therapy.

Keyword

Breast cancer; Circulating tumor cells; Extracellular nucleic acids

MeSH Terms

Breast
Breast Neoplasms
Cell Size
Humans
Neoplasm Metastasis
Neoplastic Cells, Circulating
Nucleic Acids
Prognosis
Nucleic Acids

Reference

1. Gilles C, Collignon J, Noel A, Jerusalem G, Foidart JM. [Circulating tumor cells: detection, characterization and clinical impact]. Rev Med Liege. 2011. 66:279–284.

2. Ali AM, Ueno T, Tanaka S, Takada M, Ishiguro H, Abdellah AZ, et al. Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients. Eur J Cancer. 2011. 47:2265–2272.

3. Alix-Panabieres C, Vendrell JP, Pelle O, Rebillard X, Riethdorf S, Muller V, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem. 2007. 53:537–539.

4. Miller MC, Doyle GV, Terstappen LW. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol. 2010. 2010:617421.

5. Kruck S, Gakis G, Stenzl A. Disseminated and circulating tumor cells for monitoring chemotherapy in urological tumors. Anticancer Res. 2011. 31:2053–2057.

6. Di Bernardo G, Del Gaudio S, Galderisi U, Cipollaro M. 2000 Year-old ancient equids: an ancient-DNA lesson from pompeii remains. J Exp Zool B Mol Dev Evol. 2004. 302:550–556.

7. Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas. 2009. 38:e190–e199.

8. Schuler PJ, Harasymczuk M, Schilling B, Lang S, Whiteside TL. Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods. 2011. 369:59–68.

9. Zhang LZ, Ding X, Li XY, Cen JN, Chen ZX. [In vitro effects of anti-CD44 monoclonal antibody on the adhesion and migration of chronic myeloid leukemia stem cells.]. Zhonghua Xue Ye Xue Za Zhi. 2010. 31:398–402.

10. Zuccolo J, Unruh TL, Deans JP. Efficient isolation of highly purified tonsil B lymphocytes using RosetteSep with allogeneic human red blood cells. BMC Immunol. 2009. 10:30.

11. Tondreau T, Lagneaux L, Dejeneffe M, Delforge A, Massy M, Mortier C, et al. Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential. Cytotherapy. 2004. 6:372–379.

12. Lagoudianakis EE, Kataki A, Manouras A, Memos N, Papadima A, Derventzi A, et al. Detection of epithelial cells by RT-PCR targeting CEA, CK20, and TEM-8 in colorectal carcinoma patients using OncoQuick density gradient centrifugation system. J Surg Res. 2009. 155:183–190.

13. Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert JR. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res. 2003. 162:149–155.

14. O'Driscoll L, Kenny E, Mehta JP, Doolan P, Joyce H, Gammell P, et al. Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR. Cancer Genomics Proteomics. 2008. 5:94–104.

15. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989. 46:318–322.

16. Alvarenga CA, Paravidino PI, Alvarenga M, Dufloth R, Gomes M, Zeferino LC, et al. Expression of CK19 in invasive breast carcinomas of special histological types: implications for the use of one-step nucleic acid amplification. J Clin Pathol. 2011. 64:493–497.

17. Brogi E, Murphy CG, Johnson ML, Conlin AK, Hsu M, Patil S, et al. Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Ann Oncol. 2011. 22:2597–2603.

18. Dominguez G, Silva JM, Silva J, Garcia JM, Sanchez A, Navarro A, et al. Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast Cancer Res Treat. 2001. 66:183–190.

19. Ren H, Zhao T, Wang X, Gao C, Wang J, Yu M, et al. Leptin upregulates telomerase activity and transcription of human telomerase reverse transcriptase in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 2010. 394:59–63.

20. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res. 2000. 6:3823–3826.

21. Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Falco E, Fontana V, et al. Detection of circulating tumour cells in breast cancer patients using human mammaglobin RT-PCR: association with clinical prognostic factors. Anticancer Res. 2010. 30:2377–2382.

22. Bao N, Le TT, Cheng JX, Lu C. Microfluidic electroporation of tumor and blood cells: observation of nucleus expansion and implications on selective analysis and purging of circulating tumor cells. Integr Biol (Camb). 2010. 2:113–120.

23. Mikhitarian K, Martin RH, Ruppel MB, Gillanders WE, Hoda R, Schutte del H, et al. Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: interim results of a prospective cohort study. BMC Cancer. 2008. 8:55.

24. Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, et al. CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med Oncol. 2011. 28:S129–S134.

25. Garcia V, Garcia JM, Pena C, Silva J, Dominguez G, Lorenzo Y, et al. Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett. 2008. 263:312–320.

26. Badzek S, Kelovic VL, Plestina S, Humar I, Veir Z, Mihaljevic Z. Serum HER2/ECD value in stage I and II early breast cancer - need of a lower cut-off? Wien Klin Wochenschr. 2011. 123:726–731.

27. Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E. Breast cancer and microRNAs:therapeutic impact. Breast. 2011. 20:S63–S70.

28. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011. 57:84–91.